It took Oxford University’s brightest minds decades of work to give them the expertise to develop a Covid-19 vaccine.
AstraZeneca started late-stage trials of an experimental long-acting monoclonal antibody combination drug the company hopes could be used as a so-called prophylactic to prevent Covid-19 infection in at-risk people for up to 12 months.
People who have had Covid-19 are highly unlikely to contract the disease again for at least six months after their first infection, according to a British study of healthcare workers on the frontline of the fight against the coronavirus pandemic.
U.S. and European regulators could approve Pfizer and BioNTech’s experimental Covid-19 vaccine as early as mid-December, the German firm’s chief executive said, following the release of positive trial results.
The number of reported global daily deaths from the coronavirus reached 10,816 on Nov. 17, according to a Reuters tally, the highest single-day death count as the virus’ global epicenter the United States entered winter.
Johnson & Johnson launched a new late-stage trial in Britain to test a two-dose regimen of the company’s experimental Covid-19 vaccine among thousands of volunteers, as the U.S. drugmaker’s clinical studies expand by geography and type.
The antiviral remdesivir should not be used as a routine treatment for Covid-19 patients in critical care wards, the head of one of the world’s top bodies representing intensive care doctors said, in a blow to the drug developed by U.S. firm Gilead.
Global coronavirus infections exceeded 50 million, according to a Reuters tally, with a second wave of the virus in the past 30 days accounting for a quarter of the total.
The painkiller aspirin will be evaluated as a possible treatment for Covid-19 in one of Britain’s biggest trials, which will assess whether it might reduce the risk of blood clots in people with the disease.
Late-stage trial results of a potential Covid-19 vaccine being developed by the University of Oxford and AstraZeneca could be presented in 2020 as the British government prepares for a possible vaccination rollout in late December or early 2021.
